Pevion Biotech and CEVEC Pharmaceuticals Sign Exclusive License Option Agreement
The transient CAP-T(TM) protein production technology is based on CAP® cells, a human immortalized cell line for stable protein production derived from amniocytes and developed by CEVEC. These nontumor origin cell lines exhibit high protein expression levels even for difficult to express proteins. They have been adapted to serumfree suspension culture and show posttranslational modifications that are humanlike, including authentic human glycosylation patterns. The platform allows efficient protein production from research, development and scale up to large scale manufacturing in highvolume bioreactors.
"The signing of this agreement is a major milestone for CEVEC since it represents our first exclusively granted license for a clinically highly relevant protein produced in our CAP® cells. We're proud that Pevion Biotech as one of the most innovative vaccine companies has chosen our CAP® technology expression platform to produce a technically demanding protein that so far remains a challenge to be expressed in standard cells like CHO or HEK 293," states Rainer Lichtenberger, CEO of CEVEC Pharmaceuticals.
The target protein is part of a vaccine that Pevion Biotech intends to develop based on its proprietary and marketvalidated virosome technology platform.
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC's novel proprietary human CAP® and CAP-T(TM) expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns.